Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeoVax Labs (GOVX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for GeoVax Labs (GOVX) over the last 16 years, with Q3 2025 value amounting to $5.0 million.

  • GeoVax Labs' Cash & Equivalents fell 4170.52% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 4170.52%. This contributed to the annual value of $5.5 million for FY2024, which is 1465.53% down from last year.
  • GeoVax Labs' Cash & Equivalents amounted to $5.0 million in Q3 2025, which was down 4170.52% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, GeoVax Labs' Cash & Equivalents peaked at $34.7 million during Q3 2022, and registered a low of $768859.0 during Q1 2024.
  • In the last 5 years, GeoVax Labs' Cash & Equivalents had a median value of $12.7 million in 2023 and averaged $14.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 929680.98% in 2021, then plummeted by 9677.63% in 2024.
  • GeoVax Labs' Cash & Equivalents (Quarter) stood at $11.4 million in 2021, then skyrocketed by 141.71% to $27.6 million in 2022, then tumbled by 76.63% to $6.5 million in 2023, then decreased by 14.66% to $5.5 million in 2024, then fell by 9.04% to $5.0 million in 2025.
  • Its Cash & Equivalents stands at $5.0 million for Q3 2025, versus $3.1 million for Q2 2025 and $7.4 million for Q1 2025.